Advertisement

Topics

Tibotec Therapeutics Company Profile

19:14 EDT 2nd May 2016 | BioPortfolio


News Articles [858 Associated News Articles listed on BioPortfolio]

Kesios Therapeutics raises £19 million; names executives

Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics…

D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2015-09-11....

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BT...

PTC Therapeutics, MGH ally in R&D of rare disease therapeutics

PTC Therapeutics Inc. and Massachusetts General Hospital are together developing treatments for rare, genetic disorders, including the fatal sensory and autonomic neuropathy known as familial dysauton...

Living Therapeutics

An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments

Tarveda spins platinum-based drug assets out into newco Placon Therapeutics

Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.

Intensity Therapeutics Inc.

Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masse...

AstraZeneca to collaborate with Moderna Therapeutics to develop mRNA therapeutics

Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…

Drugs and Medications [0 Results]

None

PubMed Articles [481 Associated PubMed Articles listed on BioPortfolio]

Injectable biomaterials: a perspective on the next wave of injectable therapeutics.

We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...

Pigmentation and Macular Degeneration: Is There a Role for GPR143?

Fit for the Eye: Aptamers in Ocular Disorders.

For any new class of therapeutics, there are certain types of indications that represent a natural fit. For nucleic acid ligands in general, and aptamers in particular, the eye has historically been a...

Eyes on New Product Development.

Eyes on New Product Development.

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibo...

Localized Therapeutics for the Treatment of Gastrointestinal Disorders II

The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

This is an open-label safety study to provide early access to TMC114 for HIV-1 infected patients who have failed and exhausted regimens based on commercially available antiretroviral (ARV)...

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

The primary objective is to continue the provision of etravirine (ETR) for patients who previously received ETR in a clinical pediatric trial sponsored by or in collaboration with Tibotec,...

Companies [10 Associated Companies listed on BioPortfolio]

Tibotec, Inc

Tibotec is a pharmaceutical research and development company dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need. T...

Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with off...

Tibotec Inc.

Tibotec Inc., based in Yardley, Pa., USA, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Cork, Ir...

Tibotec Pharmaceuticals

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Y...

Tibotec Therapeutics

More Information about "Tibotec Therapeutics" on BioPortfolio

We have published hundreds of Tibotec Therapeutics news stories on BioPortfolio along with dozens of Tibotec Therapeutics Clinical Trials and PubMed Articles about Tibotec Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tibotec Therapeutics Companies in our database. You can also find out about relevant Tibotec Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record